Poland · Delayed Price · Currency is PLN Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of PLN 72.76 million. The enterprise value is 72.02 million.
| Market Cap | 72.76M |
| Enterprise Value | 72.02M |
Important Dates
The last earnings date was Monday, June 1, 2026.
| Earnings Date | Jun 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomtec has 15.06 million shares outstanding. The number of shares has increased by 8.15% in one year.
| Current Share Class | 15.06M |
| Shares Outstanding | 15.06M |
| Shares Change (YoY) | +8.15% |
| Shares Change (QoQ) | +4.12% |
| Owned by Insiders (%) | 13.56% |
| Owned by Institutions (%) | 3.32% |
| Float | 10.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,425.41 |
| PB Ratio | 10.37 |
| P/TBV Ratio | 10.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.77 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -34.65 |
Financial Efficiency
Return on equity (ROE) is -83.04% and return on invested capital (ROIC) is -40.35%.
| Return on Equity (ROE) | -83.04% |
| Return on Assets (ROA) | -29.09% |
| Return on Invested Capital (ROIC) | -40.35% |
| Return on Capital Employed (ROCE) | -97.29% |
| Weighted Average Cost of Capital (WACC) | 5.98% |
| Revenue Per Employee | 938 |
| Profits Per Employee | -287,906 |
| Employee Count | 32 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -80,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.39% in the last 52 weeks. The beta is 0.29, so Genomtec's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -29.39% |
| 50-Day Moving Average | 5.13 |
| 200-Day Moving Average | 5.15 |
| Relative Strength Index (RSI) | 39.78 |
| Average Volume (20 Days) | 49,080 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of PLN 30,000 and -9.21 million in losses. Loss per share was -0.61.
| Revenue | 30,000 |
| Gross Profit | -8.10M |
| Operating Income | -8.59M |
| Pretax Income | -9.29M |
| Net Income | -9.21M |
| EBITDA | -6.06M |
| EBIT | -8.59M |
| Loss Per Share | -0.61 |
Balance Sheet
The company has 2.61 million in cash and 1.86 million in debt, with a net cash position of 744,000 or 0.05 per share.
| Cash & Cash Equivalents | 2.61M |
| Total Debt | 1.86M |
| Net Cash | 744,000 |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 7.02M |
| Book Value Per Share | 0.47 |
| Working Capital | 3.23M |
Cash Flow
In the last 12 months, operating cash flow was -9.34 million and capital expenditures -92,000, giving a free cash flow of -9.43 million.
| Operating Cash Flow | -9.34M |
| Capital Expenditures | -92,000 |
| Depreciation & Amortization | 2.53M |
| Net Borrowing | -976,000 |
| Free Cash Flow | -9.43M |
| FCF Per Share | -0.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | -28,646.67% |
| Pretax Margin | -30,976.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.15% |
| Shareholder Yield | -8.15% |
| Earnings Yield | -12.66% |
| FCF Yield | -12.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 4.69 and a Piotroski F-Score of 1.
| Altman Z-Score | 4.69 |
| Piotroski F-Score | 1 |